Guesstimates are not good enough for determining what is happening in routine care

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1885-1886

  Heong, V ^a   Ananda, S ^a,b   Tie, J ^b,c   Gibbs, P ^a,b,c  

^a Western Hospital   (Australia)

^b BioGrid Australia   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ACCURACY; AUSTRALIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; GLUCURONOSYLTRANSFERASE; HUMANS;

EID: 78649996193     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605998     Document Type: Letter

References (8)

1. Cunningham D, Pyrhonen S, James RD, Punt CJA, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352: 1413-1418 (Pubitemid 28510874)
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355: 1041-1047
3. Gibbs P, Clingan PR, Ganju V, Strickland AH, Wong SS, Tebutt NC, Underhill CR, Fox RM, Clavant SP, Leung J, Pho M, Brown TJ (2010) Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: A randomized phase II trial. Cancer Chemother Pharmacol March 24 (e-pub ahead of print)
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13): 905-914
5. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ (2007) Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. Lancet 370: 143-152
6. Shabaruddin FH, Elliott RA, Valle JW, Newman WG, Payne K (2010) Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. Br J Cancer 103: 315-323
7. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S (2009) Phase IV study of Bevacizumab in combination with infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77: 113-119
8. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22: 229-237